Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials
Authors' conclusion
Icodec improved glycaemic control to a similar degree as once-daily basal insulin comparators while maintaining low levels of clinically significant or severe hypoglycaemia. The findings support icodec use in Japanese individuals with different levels of type 2 diabetes progression.
Study context
- Population
- Japanese adults (≥20 years old) with T2D; insulin-naive (ONWARDS 1) and insulin-experienced (ONWARDS 2 and 4)
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulin
- Primary endpoint
- Change in HbA1c from baseline to end of treatment (EOT)
- Follow-up
- ONWARDS 1: Week 52; ONWARDS 2 and 4: Week 26
Methodological detailsJapanese subgroup
- Japanese subgroup
Primary result
As reported in the abstract
Change in HbA1c · baseline to EOT
- Similar reductions in HbA1c from baseline to end of treatment (EOT) in each trial for icodec and comparators
Further findings
Time in range (blood glucose 3.9-10.0 mmol/L) · EOT
- Comparable across treatment groups; time in range
- 58%-68%
Time with blood glucose below 3.0 mmol/L · EOT
- Comparable across treatment groups
- <1.0%
Safety
Combined clinically significant (blood glucose <3.0 mmol/L) or severe hypoglycaemia
- Severe events, ONWARDS 1 and 2
- 0
- Severe events, ONWARDS 4 (icodec group)
- 1
- Rates were low
- No new safety issues identified
Original publication
Efficacy and safety of once‐weekly insulin icodec versus once‐daily basal insulin in Japanese individuals with type 2 diabetes: A subgroup analysis of the ONWARDS 1, 2 and 4 trials. Diabetes Obes Metab. Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →